Versant Ventures related stories
All articles and analysis
Ceterix Orthopaedics nets $18 mlnCeterix Orthopaedics has secured $18 million in financing. Previous backers Novo A/S, Versant Ventures and 5AM Ventures participated in the round. Armentum Partners provided financial advice to Ceterix on the transaction. Based in Menlo Park, Calif., Ceterix develops surgical tools for arthroscopic procedures.
- IPO Profile: Vital Therapies Inc
Healthcare investor Muneer Satter owns about 6.4 million shares worth about $77 million at the IPO price.
- CRISPR Therapeutics grabs $25 mln from Versant Ventures
CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9.
- H.I.G. BioVentures leads Series C round for ForSight VISION5
ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5's board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.
- H.I.G. BioVentures leads Series C round for ForSight VISION5
ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5's board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.
- Versant Ventures leads $12 mln Series A funding round in AAVLife
Versant Ventures has led a $12 million Series A funding round in AAVLife, a gene therapy company focusing on rare diseases. Inserm Transfert Initiative, a French seed investment firm, participated in the funding round.
- IPO Profile: Achaogen Inc
5AM Ventures, ARCH Venture Partners, Domain Partners, Omega Funds, Venrock, Versant Ventures and Wellcome Trust collectively own 9.5 million shares worth $114 million at the IPO price.
- Sequent Medical rakes in $20 mln
Sequent Medical said Tuesday that it has received $20 million in Series D financing. Previous backer Delphi Ventures led the round with participation from Domain Associates, US Venture Partners and Versant Ventures. Headquartered in Aliso Viejo, Calif., Sequent Medical is a medical-device company focused on catheter-based neurovascular technologies.
- Vertex Venture Holdings leads $42 mln Series D funding in Holaira
Vertex Venture Holdings has led a $42 million Series D funding round in Holaira, Inc., a developer of medical devices to treat obstructive lung diseases. Other participants in the funding round include Windham Venture Partners, two strategic investors and all of Holaira's existing venture investors: Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners and Versant Ventures.
- VC-backed Achaogen debuts IPO
Achaogen has launched its IPO after pricing its 6 million shares at $12 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "AKAO." Credit Suisse Securities and Cowen and Company are the lead underwriters. Based in South San Francisco, Achaogen is a biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Its backers include 5AM Ventures, ARCH Venture Partners, Venrock, Versant Ventures, Frazier Healthcare Ventures, Domain Associates and Alta Partners.